Federal Agency Bets $160 Million on AI-Powered Gene Editing to Cure Childhood Diseases Faster
ARPA-H's THRIVE program will test multiple precision genetic therapies across rare diseases simultaneously, aiming to deliver cures within three years instead of decades.
The Advanced Research Projects Agency for Health (ARPA-H) has committed up to $160 million over five years to seven research teams developing platform-based precision genetic medicines through its THRIVE program (Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines). The initiative aims to collapse the traditional decade-long drug development timeline into just a few years for rare genetic diseases affecting children.
The program's innovative "umbrella trial" design allows researchers to test multiple treatments for multiple diseases simultaneously within a single clinical trial framework. This approach challenges the traditional "one disease, one treatment, one trial" model that has left approximately 95% of rare diseases without approved therapies—affecting millions of Americans, many of them children.
Platform Approach Promises Faster Path to Cures
The seven selected teams represent diverse approaches to in vivo gene editing. The Children's Hospital of Philadelphia is expanding a platform originally developed for neonatal-onset CPS1 deficiency to treat rare metabolic and hematological diseases. GEMMABio, supported by Profluent Bio, is leveraging artificial intelligence to create modular gene editors targeting conditions including extreme cholesterol disorders.
Other teams are addressing inborn errors of immunity (UC Berkeley's Innovative Genomics Institute), bone marrow failure disorders (St. Jude Children's Research Hospital), pediatric epilepsies (The Broad Institute), vascular genetic diseases (Massachusetts General Hospital), and rare genetic skin diseases like Epidermolysis Bullosa (Stanford University).
The program requires teams to demonstrate gene editing platforms generating multiple drug products with common safety profiles by year one, begin first-in-human umbrella trials by year three, and show successful expansion with additional products and diseases by year five.
AI and Modular Design Accelerate Development
The inclusion of AI-powered platforms signals a significant shift in genetic medicine development. Rather than designing bespoke therapies for each individual disease, these modular platforms can be rapidly adapted to target different genetic mutations using common delivery mechanisms and safety profiles.
The umbrella trial model could particularly benefit diseases affecting very small patient populations that wouldn't traditionally support the economics of standalone drug development. The program mandates that teams publish frequently and demonstrate their methods to enable replication by other rare disease researchers, potentially creating a multiplier effect beyond the initial seven teams.
Clinical Implications
For pediatric specialists and families affected by rare genetic diseases, the THRIVE program represents hope for curative treatments within 3-5 years rather than the typical decade-plus timeline. ARPA-H Director Alicia Jackson, Ph.D., and THRIVE Program Manager Daria Fedyukina, Ph.D., are overseeing the initiative, which requires both clinical and regulatory innovations from participating teams.
As these platforms advance toward clinical implementation, the rare disease therapeutic landscape may transform from a field dominated by symptomatic management to one offering genuine cures for conditions that have long been considered untreatable. Healthcare systems will need to prepare for a new paradigm in delivering precision genetic therapies, including novel deployment models and patient identification methods.
Sources
Reporting & accountability
How we maintain accuracy
Health AI Central separates reported facts, analysis, and public-source data. Readers can review our standards, request a correction, or consult the relevant research methodology before relying on a claim.